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MaBACKGROUND Endothelial cell (EC) dysfunction plays a central role in the pathogenesis of pulmonary arterial
hypertension (PAH), promoting vasoconstriction, smooth muscle proliferation, and inﬂammation.
OBJECTIVES This study sought to test the hypothesis that nebivolol, a b1-antagonist and b2,3-agonist, may improve
PAH and reverse the PAH-related phenotype of pulmonary ECs (P-EC).
METHODS We compared the effects of nebivolol with metoprolol, a ﬁrst-generation b1-selective b-blocker, on human
cultured PAH and control P-EC proliferation, vasoactive and proinﬂammatory factor production, and crosstalk with
PA smooth muscle cells. We assessed the effects of both b-blockers in precontracted PA rings. We also compared
the effects of both b-blockers in experimental PAH.
RESULTS PAH P-ECs overexpressed the proinﬂammatory mediators interleukin-6 and monocyte chemoattractant
protein-1, ﬁbroblast growth factor-2, and the potent vasoconstrictive agent endothelin-1 as compared with control cells.
This pathological phenotype was corrected by nebivolol but not metoprolol in a dose-dependent fashion. We conﬁrmed
that PAH P-EC proliferate more than control cells and stimulate more PA smooth muscle cell mitosis, a growth abnor-
mality that was normalized by nebivolol but not by metoprolol. Nebivolol but not metoprolol induced endothelium-
dependent and nitric oxide–dependent relaxation of PA. Nebivolol was more potent than metoprolol in improving cardiac
function, pulmonary vascular remodeling, and inﬂammation of rats with monocrotaline-induced pulmonary hypertension.
CONCLUSIONS Nebivolol could be a promising option for the management of PAH, improving endothelial dysfunction,
pulmonary vascular remodeling, and right heart function. Until clinical studies are undertaken, however, routine use
of b-blockers in PAH cannot be recommended. (J Am Coll Cardiol 2015;65:668–80) © 2015 by the American College of
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AND ACRONYM S
AR = adrenergic receptor
EC = endothelial cell
ET = endothelin
IPAH = idiopathic pulmonary
arterial hypertension
MCT = monocrotaline
PA = pulmonary artery
PAH = pulmonary arterial
hypertension
PASMC = pulmonary artery
smooth muscle cellT he pathogenesis of pulmonary arterial hyper-tension (PAH) involves a complex and multi-factorial process in which endothelial cell
(EC) dysfunction appears to play an integral role in
mediating the structural changes in the pulmonary
vasculature (1). An altered production of various
endothelial vasoactive mediators, such as nitric oxide
(NO), prostacyclin, endothelin (ET)-1, serotonin, and
thromboxane has been increasingly recognized in
patients with PAH. Because most of these mediators
affect the growth of smooth muscle cells, an
alteration in their production by ECs may facilitate
the development of pulmonary vascular hypertrophy
and structural remodeling characteristic of PAH (1).SEE PAGE 681
P-EC = pulmonary endothelial
cell
PH = pulmonary hypertension
SPH = secondary pulmonary
hypertensionAlthough efﬁcacious vasodilatory therapies targeting
endothelial dysfunction have been developed (2), the
survival of patients with PAH remains unsatisfactory
(55% at 3 years) (3). Recently, nonselective inhibitors
of the platelet-derived growth factor receptor
tyrosine kinase, such as imatinib, have been tested in
PAH as anti-remodeling agents. The IMPRES
(The Imatinib in Pulmonary Arterial Hypertension, a
Randomized, Efﬁcacy Study) revealed an added
beneﬁt for imatinib against a background of
conventional combination therapy but highlighted
severe side effects, such as subdural hematoma,
questioning the use of this poorly tolerated drug in
PAH (4). Hence, new therapeutic avenues are wanted.
Adrenergic receptors (ARs) represent major regu-
lators of the cardiovascular system and of EC function
in particular. Recent data revealed that sympathetic
overstimulation is strongly related to mortality, and
blockade of b-ARs in experimental pulmonary hy-
pertension (PH) improved survival and cardiac func-
tion (5–8). Although current treatment guidelines still
advise against the use of AR blockers in PAH because
of a feared induction of systemic hypotension and
reduction in exercise capacity, these promising pre-
clinical studies have been followed by still-ongoing
studies to test the safety and efﬁcacy of carvedilol
and bisoprolol in PAH patients. Given the role of the
b2-AR in endothelial function and the regulation of
pulmonary vascular tone, we investigated the effect
of nebivolol, a third-generation b-AR blocker, on EC
dysfunction in PAH. Nebivolol is a b1-antagonist and
b2,3-agonist and has direct vasodilator properties in
addition to its adrenergic-blocking characteristics.
Nebivolol has proven beneﬁcial effects on pulmonary
artery pressure, pulmonary wedge pressure, exercise
capacity, and left ventricular ejection fraction in pa-
tients with left heart disease (9). Moreover, nebivololis well-tolerated and highly effective in pa-
tients with chronic obstructive pulmonary
disease in association with arterial hyper-
tension (10).
In this study, we compared the effects of
nebivolol with metoprolol, a ﬁrst-generation
b1-selective b-blocker on cultured PAH and
control pulmonary endothelial cell (P-EC)
proliferation, vasoactive, and proinﬂam-
matory factors production and crosstalk
with PA smooth muscle cells (PASMCs). We
assessed the effects of both b-blockers in
precontracted rat PA rings. We also compared
the effects of both b-blockers in experimental
PH in rats induced by monocrotaline (MCT).
METHODS
STUDY POPULATION. Lung specimens were
obtained during lung transplantation in 6 patients
with idiopathic PAH (IPAH), 6 with secondary pul-
monary hypertension (SPH) (3 with sarcoidosis and 3
with pulmonary histiocytosis), and during lobectomy
or pneumonectomy for localized lung cancer without
PH in 6 control subjects. Control samples were either
adenocarcinoma or squamous cell carcinoma. The
sampling was always performed on the opposite site
of the carcinoma, and lobes with massive emphysema
and bronchial inﬂammation were excluded. Age was
41  10 years and 40  9 years in the patients with
IPAH and SPH and 54  12 years in the control sub-
jects. In the groups with IPAH and SPH, the mean
pulmonary artery pressure was, respectively, 67  13
mm Hg and 41  16 mm Hg; mean pulmonary vascular
resistance was 25.2  4 and 17  9 mm Hg$l–1$min$m2
and mean cardiac index was 2.1  0.3 and 4 
2 l$min–1$m–2. Transthoracic echocardiography was
performed preoperatively in the control subjects to
rule out PH. Patients with a mutation in the bone
morphogenic protein receptor II (BMPRII) gene were
excluded from this study. Study patients were part of
the French Network on Pulmonary Hypertension, a
program approved by our institutional Ethics Com-
mittee, and had given written informed consent
(Protocol N8CO–08–003, ID RCB: 2008-A00485-50,
approved on June 18, 2008).
ISOLATION AND CULTURE OF HUMAN P-ECs AND
PASMCs. Human P-ECs and PASMCs were cultured as
previously described (11) and were used for the study
between passages 3 and 5.
PREPARATION OF HUMAN P-EC–CONDITIONED
MEDIUM. P-ECs from control subjects and from IPAH
patients were seeded in 6-well plates at a density of
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67025  104 cells per well and allowed to adhere and grow
in MCDB131 medium (Invitrogen, Cergy-Pontoise,
France) supplemented with 10% fetal calf serum
(FCS), 50 U/mL of penicillin/streptomycin, 4 mmol/l
L-glutamine, 25 mmol/l 4-(2-hydroxyethyl)-1-piper-
azineethanesulfonic acid (HEPES), 10 U/ml heparin,
1 mg/ml human endothelial cell growth supplement,
and 10 ng/ml vascular endothelial growth factor
(Promocell, Heidelberg, Germany) for 24 h. The P-ECs
were then serum-starved in MCDB131 medium with or
without increasing concentrations of nebivolol or
metoprolol (106 to 104 mol/l). After incubation for
24 h, the medium was collected for PA-SMC growth
assay and for enzyme-linked immunoassays (all from
R&D Systems, Lille, France).
MEASUREMENTS OF P-EC PROLIFERATION. P-ECs
were seeded in 96-well plates at a density of 5  103
cells per well and allowed to adhere in the MCDB-131
supplemented with 15% FCS for 24 h. The P-ECs were
then serum-starved in MCDB131 medium for the next
24 h. The cells were subjected to 24 h in medium
containing 0% or 15% FCS in the presence of
increasing concentrations of nebivolol or metoprolol
(106 mol/l to 104 mol/l). During this period, the DNA
synthesis in proliferating cells was measured by use
of the DELPHIA Cell Proliferation Kits (Perkin Elmer,
Courtaboeuf, France). Each measurement was per-
formed in triplicate.
MEASUREMENTS OF PASMC PROLIFERATION. Control
PASMCs in Dulbecco’s modiﬁed Eagle’s medium
supplemented with 15% FCS were seeded in 96-
well plates at a density of 5  103 cells per well
and allowed to adhere. The cells were subjected to
48 h of growth arrest in medium containing 0%
FCS and then treated with 200 ml P-EC–conditioned
medium for 24 h. Cell growth was then measured
by use of the DELPHIA Cell Proliferation Kits
(Perkin Elmer). Each measurement was performed
in triplicate.
IN VIVO STUDY DESIGN, MEASUREMENTS, AND
TISSUE SAMPLING. Experiments were conducted
according to the European Union regulations (Direc-
tive 86/609 EEC) for animal experiments and com-
plied with our institution’s guidelines for animal care
and handling. The animal facility is licensed by
the French Ministry of Agriculture (agreement No.
B92–019–01). The Committee on the Ethics of Animal
Experiments CEEA26 CAPSud approved the study. Dr.
Perros supervised all animal experiments (agreement
delivered by the French Ministry of Agriculture for
animal experiment No. A92–392). All efforts were
made to minimize animal suffering.It has been shown that responses to PH triggers are
signiﬁcantly affected by age, because younger in-
dividuals with rapidly maturing lungs are more sus-
ceptible to these triggers (12,13). In this study, we
used very young non-adult rats at 100 g weight
exposed to MCT to get a model of very severe PH with
right heart failure.
Male Wistar rats (100 g body weight) were main-
tained in a temperature-controlled room with a
12/12-h light/dark cycle and randomly divided into: 1) a
saline-treated control group (control, n ¼ 10); 2) a
monocrotaline-exposed group (MCT, n ¼ 10); 3) an
MCT-exposed and 10 mg$kg–1$day–1 (days 14–21)
nebivolol-treated group (MCTþN10, n ¼ 10); 4) an
MCT-exposed and 10 mg/kg1/day1 (days 14–21)
metoprolol-treated group (MCTþM10, n ¼ 10);
and 5) an MCT-exposed and 100 mg$kg–1$day–1 (days
14–21) metoprolol-treated group (MCTþM100, n ¼ 10).
All rats had access to standard rat chow and water
ad libitum. For MCT administration, rats received a
single subcutaneous injection of 60 mg$kg–1 MCT
(Sigma-Aldrich, Lyon, France), which was dissolved in
1 N HCl and neutralized with 1 N NaOH. At day 21,
measurement of the right ventricular systolic pressure
(RVSP) (mm Hg), mean pulmonary artery pressure
(mPAP) (mm Hg), cardiac output (CO) ml$min–1,
and total pulmonary vascular resistances (PVR)
mm Hg$ml$min–1 were recorded as previously des-
cribed (14). After rats were exsanguinated, the right
lungs were distended by infusion of optimal cutting
temperature compound (Miles, Epernon, France)
diluted in phosphate-buffered saline (1:1) into the right
principal bronchus, quick-frozen in isopentane on dry
ice, and stored at –80C. Left lungs were formalin-
distended, ﬁxed, and parafﬁn-embedded. For Ful-
ton’s index of right ventricular hypertrophy, the ratio
of the right ventricular weight–to–left ventricular plus
septal weight (RV/LVþS) was calculated. In a second
experiment, we treated MCT-exposed rats with nebi-
volol during 14 days (days 14–28, MCTþN10, n ¼ 9), as
compared with MCT alone (n ¼ 15) and control (n ¼ 5).
In this second experiment, systolic carotid artery
pressure and heart rate were also analyzed for the
possible systemic side effects of nebivolol treatment.
PULMONARYARTERYMORPHOMETRYANDQUANTIFICATION
OF PULMONARY INFLAMMATION. After parafﬁn embed-
ding, 5-mm-thick lung sections were stained with
hematoxylin-phloxine-saffron. In each rat, 40 to 60
intra-acinar arteries were analyzed and categorized
as muscularized (fully or partially) or nonmuscu-
larized to assess the degree of muscularization.
Pulmonary macrophages were stained on 6-mm
sections of frozen tissue with a mouse anti-rat CD68
FIGURE 1 In Vitro Effects of Nebivolol and Metoprolol on
Human Pulmonary Endothelial Cell Proliferation
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Pulmonary endothelial cells (P-EC) from control and pulmonary arterial hypertension
(PAH) lungs were either cultured with basal medium, fetal calf serum (FCS), or FCS þ
nebivolol (Nebi) or FCS þ metoprolol (Meto) at 10–6 mol/l and 10–5 mol/l. Results are
expressed in europium counts (Eu count). Comparison between control and PAH:
*p < 0.05, **p < 0.01. Comparison to cells in the same group without treatment:
#p < 0.05, ##p < 0.01. n ¼ 6 in each condition.
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671(clone ED1, Serotec, Oxford, United Kingdom) and
detected with a donkey anti-mouse alexa-ﬂuor
594. Cell quantiﬁcation was performed in 4 wide
ﬁelds by use of an automated counting with a Nikon
eclipse 80i camera (Nikon France SAS, Champigny sur
Marne, France) and NIH image software (freeware,
available from: http://rsb.info.nih.gov/nih-image/
Default.html). Results are expressed as number of
cells by ﬁeld.
REAL-TIME POLYMERASE CHAIN REACTION. We
performed real-time polymerase chain reaction as
previously described (15), with the use of TaqMan
gene expression assays (ID number in brackets)
(Gapgh [Rn01775763_g1] and Bnp [Rn00676450_g1])
on a StepOnePlus system (Applied Biosystems,
Courtaboeuf, France).
ORGAN BATH STUDIES. Male Wistar rats were killed
by intraperitoneal overdose of sodium pentobarbital.
The lung was removed and the pulmonary arteries
were gently dissected of adjacent tissue. Ring seg-
ments (average diameter ¼ 1 mm and length ¼ 2 mm)
were cleaned and cut gently; care was taken to pre-
serve the endothelium. In some experiments, the
endothelium was deliberately removed by rubbing
the lumen. The arteries were then suspended in glass
organ baths containing oxygenated Krebs solution.
Resting tension of 0.2 g force was maintainedFIGURE 2 In Vitro Effects of Nebivolol and Metoprolol on Human Pulmonary Artery Smooth Muscle Cell Proliferation Induced by Pul-
monary Endothelial Cells (Pulmonary Endothelial Cell to Pulmonary Artery Smooth Muscle Cell Crosstalk)
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Pulmonary artery smooth muscle cells (PASMC) were either cultured with basal medium or human pulmonary endothelial cell (P-EC)-condi-
tioned medium from control and PAH patients, with or without nebivolol (Nebi) or metoprolol (Meto) at 10–6 mol/l, 10–5 mol/l, and 10–4 mol/l.
Results are expressed in europium counts (Eu count). Comparison between control and PAH: *p < 0.05, **p < 0.01. Comparison to cells in the
same group without treatment: #p < 0.01, ##p < 0.001. n ¼ 6 in each condition.
FIGURE 3 In Vitro Effects of Nebivolol and Metoprolol on Human Pulmonary Endothelial Cell Production of Proinﬂammatory Cytokines/Chemokines
(IL-6, IL-1b, and MCP-1), Growth Factors (PDGF, EGF, and FGF-2), and Vasoconstrictive Factor (ET-1)
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The pulmonary endothelial cells (P-ECs) from control and pulmonary arterial hypertension (PAH) lungs were serum-starved in MCDB131 medium with or without
increasing concentrations of nebivolol or metoprolol (106 to 104 mol/l). After incubation for 24 h, the medium was collected for enzyme-linked immunoassay.
Comparison between control and PAH: *p < 0.01, **p < 0.001. (A) interleukin-6, (B) interleukin-1b, (C)monocyte chemoattractant protein 1, (D) platelet-derived growth
factor subunit B, (E) epidermal growth factor, (F) ﬁbroblast growth factor 2, and (G) endothelin-1. Comparison to cells in the same group without treatment: #p < 0.05,
##p < 0.01, ###p < 0.001. n ¼ 6 in each condition.
Perros et al. J A C C V O L . 6 5 , N O . 7 , 2 0 1 5
Nebivolol in Pulmonary Hypertension F E B R U A R Y 2 4 , 2 0 1 5 : 6 6 8 – 8 0
672
FIGURE 4 In Vivo Effects of Nebivolol and Metoprolol on Hemodynamics and Right Heart Hypertrophy in
Monocrotaline-Induced Pulmonary Hypertension in Rats
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Five groups were compared: 1) saline-treated control group (control); 2) monocrotaline (MCT)-exposed group; 3) MCT-exposed and
10 mg$kg–1$day–1 (days 14–21) nebivolol-treated group (MCT þ N10); 4) MCT-exposed and 10 mg$kg–1$day–1 (days 14–21) metoprolol-treated
group (MCT þ M10); and 5) MCT-exposed and 100 mg$kg–1$day–1 (days 14–21) metoprolol-treated group (MCT þ M100). In vivo effects of
nebivolol and metoprolol on (A) right ventricular systolic pressures (RVSP) (mm Hg), (B) mean pulmonary artery pressure (mPAP) (mm Hg),
(C) cardiac output (CO) (ml$min–1), (D) total pulmonary vascular resistance (PVR) (mm Hg$min$ml–1), and (E) Fulton’s index of right ventricular
hypertrophy, calculated as the ratio of the right ventricular weight–to–left ventricular plus septal weight (RV/LVþS). Control, n ¼ 10; MCT,
n ¼ 5; MCT þ N10, n ¼ 7; MCT þ M10, n ¼ 6; MCT þ M100, n ¼ 4.
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FIGURE 5 In Vivo Effects of Nebivolol and Metoprolol on Pulmonary Vascular Remodeling and Inﬂammation in
Monocrotaline-Induced Pulmonary Hypertension in Rats
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Five groups were compared: 1) saline-treated control group (control); 2) monocrotaline MCT-exposed group; 3) MCT-exposed and
10 mg$kg–1$day–1 (days 14–21) nebivolol-treated group (MCT þ N10); 4) MCT-exposed and 10 mg$kg–1$day–1 (days 14–21) metoprolol-treated
group (MCT þ M10); and 5) MCT-exposed and 100 mg$kg–1$day–1 (days 14–21) metoprolol-treated group (MCT þ M100). The analysis of the
neomuscularization of normally non-muscularized small distal pulmonary artery (PA) (#50 mm) is a common and robust way to quantify the
degree of remodeling of the rat pulmonary vasculature. (A) Percentage of non-muscularized (NM) PA. (B) Percentage of partially muscularized
(PM) PA. (C) Percentage of fully muscularized (FM) PA. (D) Mean number of macrophages (CD68þ cells) per low-magniﬁcation ﬁeld.
(E) Representative images of pulmonary vascular remodeling and macrophage accumulation in the 5 different groups (control, MCT þ N,
MCT þ M10, and MCT þ M100). Control, n ¼ 10; MCT, n ¼ 5; MCT þ N10, n ¼ 7; MCT þ M10, n ¼ 6; MCT þ M100, n ¼ 4.
Continued on the next page
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674throughout the experiment. Tissues were allowed to
equilibrate for 2 h before the addition of any drugs.
Contraction was elicited with the use of 0.1 mmol/l
norepinephrine; at the maximal response, we added
acetylcholine (10–8 to 10–5 mol/l) to test the endo-
thelium integrity. The tissues were then washed
with fresh Krebs-Ringer solution after 60 min of re-
equilibration; subsequent contractile response to
norepinephrine was performed, and nebivolol or
metoprolol was added at increasing concentrations
(10–8 to 10–4 mol/l). The same experiments were
performed on arteries pre-treated with the NO
synthase (NOS) inhibitor NG-nitro-L-arginine methyl
ester (L-NAME) (10–4 mol/l).STATISTICAL EVALUATION. All data were veriﬁed
for normal distribution. Quantitative variables
are presented as mean  SEM. Data were analyzed
with use of the Student t test or one-way analysis of
variance and Bonferroni multiple comparisons test.
Values of p < 0.05 were considered to reﬂect statis-
tical signiﬁcance.
RESULTS
NEBIVOLOL BUT NOT METOPROLOL REDUCES HUMAN
P-ECs AND P-EC–INDUCED PASMC PROLIFERATION.
As expected (16), human P-ECs from IPAH lungs
proliferated more than did control P-ECs under basal
FIGURE 5 Continued
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FIGURE 6 Ex Vivo
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676and FCS-stimulated conditions (Figure 1). Nebivolol
signiﬁcantly decreased FCS-induced P-EC prolifera-
tion in a dose-dependent fashion by a 1.8 reduction
factor in IPAH and by 1.4 in control cells (both
p < 0.01) at 10 mmol/l. Metoprolol had no signiﬁcant
effect on FCS-stimulated proliferation of IPAH and
control P-ECs. We tested the effects of nebivolol
and metoprolol on P-EC–induced PASMC proliferation
by transferring P-EC medium conditioned with or
without b-blockers to PASMC cultures. As already
shown (17), P-EC–conditioned medium from IPAH
cells induced signiﬁcantly more PASMC proliferation
as compared with control (p < 0.01) (Figure 2). Nebi-
volol but not metoprolol decreased this mitogenic
crosstalk in a dose-dependent fashion of both IPAH
and control P-EC medium (both p < 0.001 at 10 mmol/l
nebivolol). Of note, 100 mmol/l nebivolol did not reach
a signiﬁcantly higher blocking effect as compared
with 10 mmol/l. Nebivolol had similar effects on P-ECs
from SPH lungs (Online Figures 1 and 2).
NEBIVOLOL BUT NOT METOPROLOL REDUCES THE
PATHOLOGICAL OVERPRODUCTION OF INTERLEUKIN-6,
MONOCYTE CHEMOATTRACTANT PROTEIN-1, FIBROBLAST
GROWTH FACTOR-2, AND ET-1 FOUND IN HUMAN
IPAH P-ECs. With the use of an enzyme-linked
immunoassay, we quantiﬁed the proinﬂammatoryEffects of Nebivolol and Metoprolol on
-Contracted, Rat Pulmonary Artery Rings
Ach
Nebi
Meto
Concentrations (M)
10-8 10-7 10-6 10-5 10-4
ited with 0.1 mmol/l norepinephrine. At the maximal response,
10–8 to 10–5 mol/l) was used to test the endothelium integrity.
n washed, subsequent contractile responses to norepinephrine
nebivolol or metoprolol was added at increasing concentrations
Drug-induced vasodilation is expressed as percent relaxation from
ter. n ¼ 6 rats.cytokines/chemokine (interleukin [IL]1-b, IL-6,
and monocyte chemoattractant protein 1 [MCP1]),
the growth factors (PDGF, EGF, and FGF2), and
the vasoconstrictive factor ET-1 concentrations
in P-EC–conditioned mediums. We found an over-
expression of IL-6, MCP-1, FGF2, and ET-1 in IPAH
cells (Figures 3A, 3C, 3F, and 3G) (p < 0.001, p < 0.001,
p < 0.001, and p < 0.01, respectively, in IPAH
compared with control P-EC). However, we did not
detect changes in IL1-b, PDGF, and EGF production
(Figures 3B, 3D, and 3E) in IPAH compared with con-
trol P-EC–conditioned mediums. These alterations
were either reduced (MCP-1 and FGF2) or completely
normalized (IL-6 and ET-1) by nebivolol but not
by metoprolol in a dose-dependent fashion. Nebi-
volol had similar effects on P-EC from SPH lungs
(Online Figure 3).
NEBIVOLOL HAS GREATER BENEFICIAL EFFECTS
THAN METOPROLOL ON EXPERIMENTAL SEVERE
PAH. After exposure to MCT (60 mg/kg), young Wis-
tar rats (weight, 100 g) had development of severe
PAH. At day 21, MCT-exposed rats had severe PAH
characterized by a high RVSP and high mPAP. None of
the nebivolol or metoprolol treatments were associ-
ated with signiﬁcant changes in these hemodynamic
parameters (Figures 4A and 4B). However, there were
signiﬁcant improvements in CO and PVR in the
nebivolol-treated and in the metoprolol-treated
(10 mg/kg) groups as compared with non-treated
PAH rats (p < 0.001 and p < 0.05, respectively, as
compared with MCT alone–exposed group). More-
over, nebivolol (10 mg/kg) had a better effect on CO
than did metoprolol (10 mg/kg) (p < 0.01).
Metoprolol-treated (100 mg/kg) rats had worse CO
and PVR values than did the nebivolol-treated
and the metoprolol-treated (10 mg/kg) PAH rats
(p < 0.0001 and p < 0.01, respectively) (Figures 4C
and 4D). As the result of the high PVRs that devel-
oped in the MCT-exposed rats, there was signiﬁcant
right ventricular hypertrophy assessed by means of
the Fulton index (FI ¼ RV/[LVþS]), in these animals
(p < 0.0001). In accordance with the lower PVRs
measured in the nebivolol-treated PAH rats, this
group had less RV hypertrophy (p < 0.01 as compared
with MCT rats). Metoprolol treatment, regardless of
dose, did not result in a reduction of RV hypertrophy.
There was signiﬁcantly more RV hypertrophy in the
metoprolol-treated (10 mg/kg) group than in the
nebivolol-treated group (p < 0.01) (Figure 4E). The
increase in the PVRs, heart failure, and death in
PAH was reﬂected by progressive remodeling of
pulmonary precapillary arteries. The analysis of the
neomuscularization of normally non-muscularized
CENTRAL ILLUSTRATION Pulmonary Hypertension Pathobiology and its Targeting by Nebivolol
Pulmonary artery (PA) endothelial cells from PAH patients (PAH PA-EC) overexpress the proinﬂammatory mediators interleukin (IL)-6 and monocyte chemoattractant
protein (MCP)-1, ﬁbroblast growth factor (FGF)-2, and the potent vasoconstrictive agent endothelin (ET)-1. This pathological phenotype is corrected by nebivolol. PAH
PA-EC proliferate more than do control cells and stimulate more PA smooth muscle cell mitosis, a growth abnormality that is also normalized by nebivolol. Moreover,
nebivolol induced an endothelium-dependent and nitric oxide (NO)-dependent partial relaxation of PA. All taken together, nebivolol reduces pulmonary vascular
remodeling and inﬂammation.
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678(NM) small distal PA (#50 mm) is a common and
robust way to quantify the degree of remodeling
of the rat pulmonary vasculature. We found a
dramatic decrease in the low-resistance NM PA in
MCT-exposed rats as compared with control rats
(p < 0.0001) and its corollary, a dramatic increase
in high-resistance, fully muscularized (FM) PA
(p < 0.0001) (Figures 5A and 5C). In addition, there
was an increase in partially muscularized (PM) PA
in MCT-exposed rats as compared with control
(p < 0.0001) (Figure 5B). Nebivolol (10 mg/kg)
increased the percentage of NM PA (p < 0.01 as
compared with MCT alone–exposed group), whereas
metoprolol (both doses) further decreased this
percentage, as compared with MCT-exposed rats
(both p < 0.0001) (Figure 5A). In contrast, nebivolol
decreased the percentage of PM and FM PA (both
p < 0.01), whereas metoprolol (10 mg/kg) decreased
the percentage of PM PA (p < 0.01) but increased
further the percentage of FM PA (p < 0.01) as
compared with MCT-exposed rats. Metoprolol
(100 mg/kg) had higher percentages of both PM
and FM as compared with nebivolol-treated rats
(p < 0.01 and p < 0.0001, respectively) (Figures 5A
and 5C). At last, nebivolol decreased signiﬁcantly
the accumulation of macrophages in the MCT lung
(p < 0.05) (Figure 5D). Representative images of the
pulmonary vascular remodeling and macrophage
accumulation in the 5 different groups (control,
MCT, MCTþN, MCTþM10, and MCTþM100) are
shown in Figure 5E. By treating MCT-exposed rats
for a longer duration (14 days, from day 14 to day
28 after MCT), we observed more beneﬁcial effects
of nebivolol on RVSP, mPAP, and RV hypertrophy,
associated with a decrease in the right ventricular
BNP expression. CO was not improved, but PVR
was reduced (Online Figure 4). However, it is
difﬁcult to compare the effects of nebivolol at
day 21 (considered as early and compensated PH)
and at day 28 (late and decompensated PH). The
effect on the distal muscularization was similar
as observed at day 28 as compared with day 21
(Online Figure 5).
NEBIVOLOL BUT NOT METOPROLOL INDUCED
VASODILATION OF PRECONTRACTED RAT PA
RINGS. Nebivolol allowed a vasodilation of z20% on
norepinephrine-induced, precontracted rat PA rings
at 10–5 and 10–4 mol/l, whereas metoprolol had no
effect (Figure 6). When the endothelium was removed
or when the NOS was inhibited by L-NAME, Ach- and
nebivolol-induced PA vasodilation were totally abol-
ished (data not shown).DISCUSSION
We found that PAH P-ECs overexpressed the proin-
ﬂammatory mediators IL-6 and MCP-1, the growth
factor FGF2, and the potent vasoconstrictive agent
endothelin-1 as compared with control cells. This
pathological phenotype was corrected by the use of
nebivolol but not metoprolol in a dose-dependent
fashion. We conﬁrmed that PAH P-ECs proliferate
more than control cells and stimulate more PASMC
mitosis, a growth abnormality that was normalized
by nebivolol but not by metoprolol. Interestingly,
nebivolol had similar effects on P-ECs from
SPH lungs. Nebivolol induced an endothelium-
and NO-dependent partial relaxation of PA. At last,
nebivolol was more potent than was metoprolol
in improving cardiac function, pulmonary vas-
cular remodeling, and inﬂammation of rats with
MCT-induced PH.
Nebivolol is a third-generation b-adrenergic re-
ceptor blocker with vasodilator properties mediated
by stimulation of endothelial NO synthase (eNOS)
(18). Accordingly, we found that L-NAME totally
abolished the vasodilatory properties of nebivolol
on isolated PA in organ bath experiments. In our
study, nebivolol was more potent than metoprolol
to correct PAH-related endothelial dysfunction
in vitro and to improve experimental PAH in rats.
These results are consistent with previous work
showing that nebivolol but not metoprolol nor-
malizes endothelial function, reduces superoxide
formation, increases NO bioavailability, and in-
hibits up-regulation of the activity and expression
of the vascular NAD(P)H oxidase in a model of
angiotensin II–induced oxidative stress (19), thus
preventing eNOS uncoupling. Nebivolol also re-
duces the levels of the circulating eNOS inhibitor
asymmetric dimethylarginine, which probably con-
tributes to increased vascular NO bioavailability,
whereas metoprolol does not contribute (20). We
also observed that nebivolol corrected better than
did metoprolol the proinﬂammatory phenotype of
the P-ECs from PAH patients (reduction of IL-6
and MCP1 expression) and dramatically decreased
macrophage accumulation in the MCT lung.
In vivo, the anti-inﬂammatory properties of nebi-
volol, and, to a lesser extent, metoprolol, may also
be due to a direct effect on immune cells, because
catecholamines are actively produced by macro-
phages and have the capacity to act in an autocrine
way on ARs to regulate macrophage production of
IL-1b, which has a key role in the inﬂammatory
response (21). In our study, nebivolol treatment
PERSPECTIVES
COMPETENCY IN MEDICAL KNOWLEDGE: The
third-generation b-adrenergic receptor blocker nebivolol
appears to attenuate experimental pulmonary hypertension
by correcting endothelial dysfunction (Central Illustration).
TRANSLATIONAL OUTLOOK: Although b-adrenergic
receptor blockade is not currently recommended for treatment
of patients with pulmonary arterial hypertension, clinical trials
of nebivolol are warranted on the basis of this distinguishing
mechanism of action.
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679decreased vascular remodeling in experimental PH,
whereas metoprolol worsened it. One reason for
this divergence, apart from all beneﬁcial effects of
nebivolol that are not shared with metoprolol, may
be an antagonist effect of metoprolol on vascular
b2-ARs even if metoprolol has a good b1 selectivity
(b1/b2 selectivity ¼ 74) (18). This also may be true
at a higher dose of metoprolol (100 mg/kg). High
concentrations of metoprolol may favor PA
constriction and PASMC proliferation. MCT expo-
sure is a model of severe PH, in which all rats die
of right heart failure, and both b-blockers may
have improved right heart function/coupling.
Nebivolol has been shown to preserve left ven-
tricular function, cause peripheral vasodilation,
maintain stroke volume and cardiac output, and
preserve cardiac chronotropism during exertion
(18). Furthermore, compared with bisoprolol, ne-
bivolol did not cause an increase in pulmonary
artery wedge pressure (9). This could further
explain the superiority of nebivolol over metopro-
lol to improve experimental PH. However, one
must be aware that the MCT-induced PH is
considered by some to be an acute toxic model
characterized by acute/subacute damage of the
peripheral vasculature of the lung and other organs
(kidney, liver, and heart) (13). For this reason, we
plan to test the efﬁcacy of nebivolol in a piglet
model of chronic PH, which is more relevant to the
human condition (22–24).CONCLUSIONS
Our work demonstrates for the ﬁrst time that nebi-
volol could be a promising option for the manage-
ment of PAH, improving endothelial dysfunction,
pulmonary vascular remodeling, and right heart
function. Until clinical studies are undertaken, how-
ever, routine use of b-blockers in PAH cannot be
recommended.
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